Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 1997

View Archived Issues

New alinidine analogues described

Ansan announces merger with Discovery Laboratories and licensing agreement with Titan

Garlic suggested to merit further evaluation for H. pylori infections

Cortecs and Astra promotion agreement for Helisal One Step

Positive results reported for MRSA test

NPY antagonists developed at Thomae

Amgen: Q2 1997 highlights

Pierre Fabre prepares compounds for hypercholesterolemia/atherosclerosis

Asta prepares and evaluates targeted cytotoxic anthracycline analogues

Phosphodiesterase inhibitors from Schering-Plough

Drug interactions and clinical efficacy of pazufloxacin/pazufloxacin mesilate

HSR-903: antichlamydial activity and drug interactions

Clinafloxacin vs. imipenem for empiric therapy of febrile granulocytopenic patients

DU-6859a: dose-finding study in UTI

FDA grants raloxifene NDA priority review status

Genetic and molecular pathogenesis of IDDM

More light shed on leptin and leptin receptors

Roberts seeks approval to begin clinical studies of gastrointestinal drug

Antibacterial activity and clinical efficacy of grepafloxacin reported

Quinolones remain at the forefront of antiinfective therapy

DynaGen expands ImmuDyn development

FDA clears potent pain reliever without opioid side effects from Wyeth-Ayerst

Potent, orally active azole antifungal from Bayer

Nicotine Inhaler launched in The Netherlands

New bactericidal antiseptic from Otsuka

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...